Inhibitory effects of roquefortine on hepatic cytochromes P450.
Aninat
C
C
CEA Saclay, Département de la Recherche Médicale, Service Pharmacologie et d'Immunologie, Gif sur Yvette, France.
Delaforge
M
M
D000818:Animals; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004873:Ergolines / Q000737:chemistry / Q000494:pharmacology*; D006576:Heterocyclic Compounds, 4 or More Rings; D007211:Indoles; D008099:Liver; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D006899:Mixed Function Oxygenases / Q000378:metabolism; D015394:Molecular Structure; D009249:NADP / Q000378:metabolism; D010879:Piperazines; D051381:Rats; D013739:Testosterone / Q000378:metabolism
D065607:Cytochrome P-450 Enzyme Inhibitors; D004873:Ergolines; D006576:Heterocyclic Compounds, 4 or More Rings; D007211:Indoles; D010879:Piperazines; D013739:Testosterone; D009249:NADP; C012536:roquefortine; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A